Nanoparticles designed to mimic how viruses penetrate the gut achieved a 50% blood glucose reduction when loaded with insulin and taken orally by diabetic rats, with 2.1-fold better bioavailability than direct intestinal insulin delivery.
~50% blood glucose reduction via oral deliveryInsulin-loaded virus-mimicking nanoparticles achieved this in diabetic rats, with 2.1-fold higher bioavailability than direct intestinal insulin administration
What the researchers found
Virus-mimicking mesoporous silica nanoparticles coated with the cell-penetrating peptide KLPVM and glutaric anhydride achieved near-neutral surface charge (ζ-potential -0.49 mV), enabling them to penetrate the intestinal mucus layer without binding to mucin — unlike positively charged nanoparticles (ζ-potential +35.00 mV). Transepithelial transport was 2.4-fold higher than unmodified nanoparticles. In diabetic rats, insulin loaded into these nanoparticles reduced blood glucose by nearly 50%, with 2.1-fold higher bioavailability than insulin administered directly into the jejunum. No significant toxicity was observed in preliminary in vitro or in vivo studies.
Why it matters
Insulin and most peptide drugs cannot currently be taken orally because they are destroyed in the stomach and cannot pass through the intestinal mucus and epithelial barriers. This virus-mimicking approach solves both problems simultaneously — using a neutral, hydrophilic surface to slip through mucus (like viruses do) and a cell-penetrating peptide to cross the intestinal wall. Success here could transform diabetes management and open the door for oral delivery of many other peptide therapeutics.
The numbers in context
6 nm pore diameter · ζ-potential: -0.49 mV (neutral) · Permeability: 14.61 × 10⁻⁵ cm/s · 2.4-fold higher transport vs. unmodified · ~50% blood glucose reduction · 2.1-fold bioavailability increase · No significant toxicity
How the study worked
Researchers fabricated mesoporous silica nanoparticles with 6 nm pores for insulin loading, then coated them with the cationic cell-penetrating peptide KLPVM and anionic glutaric anhydride to create a near-neutral surface. Mucus penetration was tested against mucin in vitro. Intestinal transport was measured using Caco-2/E12 cell co-culture models. Endocytosis pathways were characterized. Insulin stability was confirmed under simulated intestinal conditions. In vivo testing in diabetic rats measured blood glucose reduction and insulin bioavailability compared to direct jejunal insulin administration.
Who was studied
In vitro cell culture models (Caco-2/E12) and in vivo diabetic rat model
What this study cannot tell us
While the diabetic rat results are promising, animal models do not always predict human responses. The study used relatively small numbers of animals and did not assess long-term safety or repeated dosing. The manufacturing scalability of these nanoparticles for commercial production was not addressed. Human clinical trials would be needed to confirm efficacy and safety.
How to read the evidence
This is a preclinical study combining in vitro cell models with an in vivo diabetic rat model. While the results are promising, the technology has not been tested in humans, and animal results in drug delivery often do not directly translate to clinical success.
When this study was published
Published in 2021, this represents recent work in the rapidly advancing field of oral peptide drug delivery. Numerous groups are pursuing similar approaches, though no oral insulin product using this type of technology has yet reached clinical use.
The bigger picture
Oral delivery of peptide and protein drugs is one of the biggest unsolved challenges in pharmaceutical science. Many important medications — insulin, GLP-1 agonists, growth hormone — require injection because they can't survive the gastrointestinal tract. This virus-mimicking approach is part of a broader effort to develop oral peptide delivery technologies that could transform how these medications are administered, improving patient compliance and quality of life.
Questions still open
- Can this virus-mimicking nanoparticle approach be scaled for commercial manufacturing and maintain its performance?
- Would the blood glucose reduction be sufficient and consistent enough in humans to replace injectable insulin?
- Could this same delivery platform be adapted for other peptide drugs like GLP-1 agonists or growth hormone?
Common questions
Why can't insulin be taken as a pill today?
How do viruses inspire better drug delivery?
Read the original research
Virus-Mimicking Mesoporous Silica Nanoparticles with an Electrically Neutral and Hydrophilic Surface to Improve the Oral Absorption of Insulin by Breaking Through Dual Barriers of the Mucus Layer and the Intestinal Epithelium.
ACS applied materials & interfaces, 13(15), 18077-18088
Citation
Zhang, Yi; Xiong, Mengting; Ni, Xiaomin; Wang, Jingrou; Rong, Hehui; Su, Yuqing; Yu, Shihui; Mohammad, Imran Shair; Leung, Sharon Shui Yee; Hu, Haiyan. (2021). Virus-Mimicking Mesoporous Silica Nanoparticles with an Electrically Neutral and Hydrophilic Surface to Improve the Oral Absorption of Insulin by Breaking Through Dual Barriers of the Mucus Layer and the Intestinal Epithelium.. ACS applied materials & interfaces, 13(15), 18077-18088. https://doi.org/10.1021/acsami.1c00580